Results 51 to 60 of about 1,660 (124)
Novel 2-mercapto imidazole and triazole derivatives as potent TGR5 receptor agonists
Medicine in Drug Discovery, 2019 TGR5 is a bile acid G protein-coupled receptor (GPCR), which is an attractive therapeutic target for the treatment of obesity, and its highly associated Type 2 diabetes.
Sameer Agarwal +7 more
doaj +1 more source
, 2011 <i>Background/Aims:</i> TGR5 is a plasma membrane-bound, G-protein-coupled receptor for bile acids. TGR5 mRNA has been detected in a variety of tissues, including liver.
Dieter Häussinger, Verena Keitel
core +1 more source
Small, EarlyView.Schematic illustration of the construction of MM‐NTU, its cardiac‐targeting behavior, and its light‐activated therapeutic mechanism. Thylakoids isolated from spinach chloroplasts were processed into nano‐thylakoid units (NTU) and further camouflaged with cardiomyocyte membranes to generate MM‐NTU.
Haohui Fan +13 more
wiley +1 more source
Cell Death and Disease, 2023 Diabetic retinopathy (DR) is a serious and relatively under-recognized complication of diabetes. Müller glial cells extend throughout the retina and play vital roles in maintaining retinal homeostasis.
Yan Li +8 more
doaj +1 more source
Liver Research, 2022 Background and aims: Diet-induced obesity and metabolic syndrome can trigger the progression of fatty liver disease to non-alcoholic steatohepatitis and fibrosis, which is a major public health concern.
Jessica M. Ferrell +6 more
doaj +1 more source
Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy
VIEW, EarlyView.This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley +1 more source
EBioMedicine, 2018 Background: The mechanism by which Roux-en-Y Gastric Bypass (RYGB) increases the secretion of glucagon-like peptide-1 (GLP-1) remains incompletely defined.
Hening Zhai +9 more
doaj +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Frontiers in Pharmacology, 2015 Gpbar1 (TGR5), a membrane-bound bile acid receptor, is well known for its roles in regulation of energy homeostasis and glucose metabolism. Here we show that mice lacking TGR5 were much more susceptible to lipopolysaccharide (LPS)-induced acute gastric ...
Cong eGuo +8 more
doaj +1 more source
Gut microbiota as a novel therapeutic target for eating disorders and obesity
British Journal of Pharmacology, EarlyView.The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė +5 more
wiley +1 more source